Cancer drug research has been aided tremendously by the recent identification of the role of several kinases in signal transduction pathways involved in the progression of many cancers including several types of leukemias, prostate, ovarian, brain, breast and lung carcinomas. The emergence of novel inhibitors of these kinases in phase I, II and III clinical trials against cancer is indicative of the importance of receptor-mediated signaling in modern therapeutic interventions against cancer. The primary objective of our laboratory is to develop new models designed to enhance the efficacy of signal transduction inhibitors in the treatment of refractory tumours and to develop them as probes for chemical proteomics and personalized medicine.
Dr. Bertrand J. Jean-Claude, Professor and Dr. Ana Belen Fraga Timiraos, Research Associate
Supporting Agencies
Canadian Institute of Health Research (CIHR)
McGill University Health Center Foundation
Cancer Research Society Inc. (CRS)
Past Funders
National Cancer Institute of Canada (NCIC)
http://www.ncic.cancer.ca/
National Cancer Institute of Canada (NCIC)/Canadian Breast Cancer Research Initiative (CBRCI)
http://www.breast.cancer.ca/
National Cancer Institute of Canada (NCIC)/Canadian Prostate Cancer Research Initiative (CPRCI)
https://www.prostateresearch.ca
Canadian Institute of Health Research (CIHR)/Proof-of-Concept Program (POP)
http://www.cihr-irsc.gc.ca/
Leukemia Research Fund of Canada
http://www.leukemia.ca
Fonds de la Recherche en Santé du Québec (FRSQ), Québec, Canada
http://www.frsq.gouv.qc.ca
Fonds pour la Formation des Chercheurs et l’Aide à la Recherche, Québec (FCAR), Québec, Canada
http://www.fcar.qc.ca/
Wendy Will Case Cancer Fund (WWCCF), Chicago, USA
http://www.wwccf.org/